360 related articles for article (PubMed ID: 21531577)
1. Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials.
Benza RL; Gomberg-Maitland M; Naeije R; Arneson CP; Lang IM
J Heart Lung Transplant; 2011 Sep; 30(9):982-9. PubMed ID: 21531577
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
[TBL] [Abstract][Full Text] [Related]
3. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
Cabrol S; Souza R; Jais X; Fadel E; Ali RH; Humbert M; Dartevelle P; Simonneau G; Sitbon O
J Heart Lung Transplant; 2007 Apr; 26(4):357-62. PubMed ID: 17403477
[TBL] [Abstract][Full Text] [Related]
4. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease.
Oudiz RJ; Schilz RJ; Barst RJ; Galié N; Rich S; Rubin LJ; Simonneau G;
Chest; 2004 Aug; 126(2):420-7. PubMed ID: 15302727
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension.
Lang I; Gomez-Sanchez M; Kneussl M; Naeije R; Escribano P; Skoro-Sajer N; Vachiery JL
Chest; 2006 Jun; 129(6):1636-43. PubMed ID: 16778286
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.
Channick RN; Olschewski H; Seeger W; Staub T; Voswinckel R; Rubin LJ
J Am Coll Cardiol; 2006 Oct; 48(7):1433-7. PubMed ID: 17010807
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil.
Barst RJ; Galie N; Naeije R; Simonneau G; Jeffs R; Arneson C; Rubin LJ
Eur Respir J; 2006 Dec; 28(6):1195-203. PubMed ID: 16899485
[TBL] [Abstract][Full Text] [Related]
8. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan.
Benza RL; Rayburn BK; Tallaj JA; Pamboukian SV; Bourge RC
Chest; 2008 Jul; 134(1):139-45. PubMed ID: 18403673
[TBL] [Abstract][Full Text] [Related]
9. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension.
Gomberg-Maitland M; Tapson VF; Benza RL; McLaughlin VV; Krichman A; Widlitz AC; Barst RJ
Am J Respir Crit Care Med; 2005 Dec; 172(12):1586-9. PubMed ID: 16151039
[TBL] [Abstract][Full Text] [Related]
10. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension.
Sitbon O; Manes A; Jais X; Pallazini M; Humbert M; Presotto L; Paillette Ld; Zaccardelli D; Davis G; Jeffs R; Simonneau G; Galie N
J Cardiovasc Pharmacol; 2007 Jan; 49(1):1-5. PubMed ID: 17261956
[TBL] [Abstract][Full Text] [Related]
11. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects.
Sitbon O; Beghetti M; Petit J; Iserin L; Humbert M; Gressin V; Simonneau G
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():25-31. PubMed ID: 16919007
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial.
Tapson VF; Gomberg-Maitland M; McLaughlin VV; Benza RL; Widlitz AC; Krichman A; Barst RJ
Chest; 2006 Mar; 129(3):683-8. PubMed ID: 16537868
[TBL] [Abstract][Full Text] [Related]
13. The role of treprostinil in the management of pulmonary hypertension.
Skoro-Sajer N; Lang I
Am J Cardiovasc Drugs; 2008; 8(4):213-7. PubMed ID: 18690755
[TBL] [Abstract][Full Text] [Related]
14. Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion.
McSwain CS; Benza R; Shapiro S; Hill N; Schilz R; Elliott CG; Zwicke DL; Oudiz RJ; Staszewski JP; Arneson CP; Wade M; Zaccardelli D; McLaughlin V
J Clin Pharmacol; 2008 Jan; 48(1):19-25. PubMed ID: 18094217
[TBL] [Abstract][Full Text] [Related]
15. Transition From Subcutaneous or Inhaled Treprostinil to Oral Treprostinil at Home in Patients With Pulmonary Arterial Hypertension: A Retrospective Case Series.
Ackerbauer KA; Tandon R
J Pharm Pract; 2018 Apr; 31(2):163-166. PubMed ID: 28464760
[TBL] [Abstract][Full Text] [Related]
16. Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension--seven sites, United States, 2003-2006.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2007 Mar; 56(8):170-2. PubMed ID: 17332729
[TBL] [Abstract][Full Text] [Related]
17. Use of subcutaneous treprostinil in pediatric pulmonary arterial hypertension-Bridge-to-transplant or long-term treatment?
Ablonczy L; Tordas D; Kis E; Szatmári A
Pediatr Transplant; 2018 Mar; 22(2):. PubMed ID: 29266571
[TBL] [Abstract][Full Text] [Related]
18. Prostanoid therapy for pulmonary arterial hypertension.
Badesch DB; McLaughlin VV; Delcroix M; Vizza CD; Olschewski H; Sitbon O; Barst RJ
J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):56S-61S. PubMed ID: 15194179
[TBL] [Abstract][Full Text] [Related]
19. Treprostinil for pulmonary hypertension.
Vachiéry JL; Naeije R
Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):183-91. PubMed ID: 15151467
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous treprostinil in congenital heart disease-related pulmonary arterial hypertension.
Skoro-Sajer N; Gerges C; Balint OH; Kohalmi D; Kaldararova M; Simkova I; Jakowitsch J; Gabriel H; Baumgartner H; Gerges M; Sadushi-Kolici R; Celermajer DS; Lang IM
Heart; 2018 Jul; 104(14):1195-1199. PubMed ID: 29436381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
